Answers are grounded in this paper and cite their sources.
Meningiomas are the most common primary intracranial tumors, and accurate imaging plays a central role in their diagnosis, risk assessment, treatment planning, and follow-up. Although many meningiomas are slow-growing, their clinical behavior can vary widely, with some tumors showing aggressive growth, postoperative recurrence, or complex extension into the skull base, bone, orbit, or dural venous sinuses. MRI and CT remain the standard imaging modalities for anatomic assessment; however, both have important limitations. MRI may be unable to reliably distinguish a residual or recurrent tumor from postoperative scarring, fibrosis, or radiation-related changes, whereas CT may be limited in differentiating reactive hyperostosis from true osseous tumor infiltration. Molecular imaging with 68Ga-DOTATOC PET/CT has emerged as a valuable complementary technique because of its high affinity for somatostatin receptor subtype 2, which is strongly expressed in most meningiomas. By providing high lesion-to-background contrast, 68Ga-DOTATOC PET/CT may improve lesion conspicuity and provide complementary information about disease extent in selected cases. Available evidence is strongest for problem-solving applications involving equivocal lesions and delineation of skull base, osseous, or optic nerve sheath disease, as well as confirmation of somatostatin receptor expression when receptor-targeted therapy is being considered. Other proposed applications, including tumor grading, prognostication, surgical planning, radiotherapy target refinement, quantitative response assessment, and routine surveillance, remain emerging and require prospective validation. This mini review summarizes the current applications, technical considerations, and limitations of 68Ga-DOTATOC PET/CT in meningioma management.
No takes yet. Share an insight, caveat, or question.
Usmani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: